Market Alert: ASX200 at Critical Support – Reversal or Further Fall?

4DMedical Announces AU$6.5 million Cost Reduction Program to Drive Growth.

Mar 26, 2025

4DMedical Limited (ASX: 4DX) has unveiled a cost reduction initiative set to deliver AU$6.5 million in annualized savings, ensuring long-term financial sustainability. The measures, which include a workforce reduction of 25 full-time employees, complement the company’s prior operating expenditure cuts, bringing 1H FY25 net spending down by 11% compared to 2H FY24. Despite these reductions, 4DMedical remains committed to its core growth strategies, including advancing clinical evidence, expanding commercial partnerships, and accelerating the launch of CT: VQ after FDA clearance. 

The company reassures stakeholders that these cost-saving initiatives will not hinder revenue growth or key milestones. Alongside these changes, 4DMedical has also announced leadership updates, with Chris Cox stepping in as Interim CFO and Hamish George as the new Company Secretary. With a strengthened financial position and continued innovation in respiratory imaging, 4DMedical is well-positioned for future success.

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com